Table 1 Cut backs of internal research and development jobs in the western hemisphere (Europe and USA), September 2012
Recent layoffs in big pharmaceutical companies | |||
|---|---|---|---|
Ranking by 2011 sales | Company | Date | Notes |
1 | Novartis | January 2012 | 2,000 US sales jobs |
2 | Sanofi | Imminent | Reportedly up to 2,000 French jobs |
3 | Pfizer | 2005 | Still another 12,100 of planned 60,000 jobs to be cut |
4 | Roche | June 2012 | Nutley site to close, 1,000 R and D jobs |
5 | GlaxoSmithKline | NA | Ongoing restructuring, no specific job target announced |
6 | Merck & Co | July 2011 | 12% to13% workforce reduction, in addition to earlier cuts following Schering-Plough takeover |
7 | Johnson & Johnson | November 2009 | 7,000 to 8,200 jobs |
8 | Abbott Laboratories | January 2012 | 700 manufacturing jobs |
9 | Bristol-Myers Squibb | NA | Ongoing, 295 jobs cut so far in 2012 |
10 | AstraZeneca | Feb 2012 | 7,300 jobs, including 2,200 in R and D |